Sponsors (23)
The bill substantially expands access to no‑cost, evidence‑based HIV prevention and funds outreach and provider support—improving prevention for many Americans—while imposing meaningful federal and private costs, administrative burdens, privacy and litigation risks, and potential gaps for non‑FDA or off‑label approaches.
Medicaid, CHIP, Medicare beneficiaries, federal employees, veterans, TRICARE/IHS patients, and others on public plans will get no‑cost coverage of FDA‑approved HIV prevention drugs and associated services (with preauthorization removed and grandfathered‑plan exemptions prohibited), expanding access to prevention across major federal and state programs.
Uninsured, underinsured, and people in high‑HIV‑burden communities will gain increased access to PrEP/PEP drugs, clinical services, adherence support, navigators, and funding for FQHCs/rural clinics through federal grants and targeted outreach and provider training.
People who use HIV‑prevention medication gain anti‑discrimination protections: they cannot be denied or limited life, disability, or long‑term care coverage, cannot be forced to stop prevention medication to obtain coverage, and cannot be charged premiums solely for using such medication, with state regulators able to enforce these prohibitions.
Taxpayers, beneficiaries, and insurers may face substantially higher costs from expanded no‑cost coverage across Medicaid/Medicare/federal programs, plus multi‑year grant programs and national outreach campaigns, potentially increasing federal spending, program costs, or insurance premiums.
State governments, insurers, employers, clinics, and community organizations will incur added administrative and compliance burdens — collecting and reporting claims/cost‑sharing data for years, changing communications/claims processes to protect dependent privacy, implementing rapid Medicaid/CHIP changes, and managing grant applications and reporting.
Private rights of action, class‑action exposure, public naming of noncompliant plans, and fee‑shifting increase litigation and reputational risks for insurers, employers, nonprofits, and possibly government entities, which can drive defensive behavior and higher compliance/legal costs.
Based on analysis of 20 sections of legislative text.
Requires no‑cost coverage and limits preauthorization for FDA‑approved HIV prevention drugs/services, adds privacy and nondiscrimination protections, funds education and grants, sets reporting and enforcement rules.
Introduced March 4, 2026 by Tina Smith · Last progress March 4, 2026
Requires private and federal group health plans to cover FDA‑approved HIV prevention drugs (PrEP and PEP) and related clinical services without cost‑sharing and generally without preauthorization, while strengthening privacy protections, banning life/disability/long‑term care insurer discrimination for people who take HIV‑prevention medication, funding education campaigns and grants for PrEP/PEP access, creating monitoring and reporting requirements for plans, and creating a private right of action to sue for violations. The bill also directs HHS/CDC to run public and provider education campaigns, establishes a federal grant program for states, tribes, and community providers, and requires data reporting and enforcement measures over a multi‑year period.